Formulations for coated microprojections having controlled solubility

• US 20050123507A1
• Filed: 01/12/2005
• Published: 06/09/2005
• Est. Priority Date: 06/30/2003
• Status: Abandoned Application

• Current Assignee: ALZA Corporation (Johnson & Johnson)
• Original Assignee: ALZA Corporation (Johnson & Johnson)
• Inventors: Cormier, Michel J. N., Maa, Yuh-Fun, Ameri, Mahmoud, Lin, WeiQi
• Application Number:
  US11/034,891
• Publication Number:
  US 20050123507A1
• Time in Patent Office: Days
• US Class Current: 424/85.100
• CPC Class Codes: A61B 17/205 Vaccinating by means of needles or other puncturing devices
• CPC Class Codes: A61K 9/0021 Intradermal administration, e.g. through microneedle arrays, needleless injectors mechanical aspects A61M
• CPC Class Codes: A61M 2037/0046 Solid microneedles
• CPC Class Codes: A61M 2037/0061 Methods for using microneedles
• CPC Class Codes: A61M 37/0015 by using microneedles

Abstract

The invention provides for a formulation for coating one or more microprojections using a non-volatile counterion to improve solubility of a biologically active agent. The invention also includes formulations having a volatile counterion to reduce the solubility of a portion of the biologically active agent.

Claims

1. A composition for coating a transdermal delivery device having stratum corneum-piercing microprojections comprising a formulation of a biologically active agent, a non-volatile counterion and a volatile counterion, wherein said non-volatile counterion causes the formation of a first species of said biologically active agent that has improved solubility when said formulation is dried and wherein said volatile counterion causes the formation of a second species of said biologically active agent that has reduced solubility when said formulation is dried.

2. The composition of claim 1, wherein said first species is adapted to rapidly provide a therapeutically relevant blood level of said biologically active agent when said formulation is allowed to dissolve in a bodily fluid.

3. The composition of claim 1, wherein said second species is adapted to provide a sustained therapeutically relevant blood level of said biologically active agent when said formulation is allowed to dissolve in a bodily fluid.

4. The composition of claim 1, comprising approximately equimolar amounts of said non-volatile counterion and said volatile counterion.

5. The composition of claim 1, wherein said formulation has a pH, said biologically active agent has a positive charge at said formulation pH and said non-volatile counterion comprises a non-volatile weak acid.

8. The composition of claim 1, wherein said formulation has a pH, said biologically active agent has a positive charge at said formulation pH and said non-volatile counterion comprises a strong acid.

9. The composition of claim 8, wherein said strong acid has at least one pKa lower than about 2.

10. The composition of claim 9, wherein said strong acid is selected from the group consisting of hydrochloric acid, hydrobromic acid, nitric acid, sulfonic acid, sulfuric acid, maleic acid, phosphoric acid, benzene sulfonic acid and methane sulfonic acid.

11. The composition of claim 1, wherein said formulation has a pH, said biologically active agent has a positive charge at said formulation pH and said non-volatile counterion comprises an acidic zwitterion.

12. The composition of claim 11, wherein said acidic zwitterion has at least two acidic pKas and at least one basic pKa, so that there is at least one acidic pKa more than said basic pKas.

13. The composition of claim 12, wherein said acidic zwitterion is selected from the group consisting of glutamic acid and aspartic acid.

14. The composition of claim 1, wherein said formulation has a pH, said biologically active agent has a negative charge at said formulation pH and said non-volatile counterion comprises a non-volatile weak base.

15. The composition of claim 14, wherein said non-volatile weak base has a basic pKa and a property selected from the group consisting of a melting point higher than about 50°

C. and a boiling point higher than about 170°

C. at atmospheric pressure.

16. The composition of claim 15, wherein said non-volatile weak base is selected from the group consisting of monoethanolomine, diethanolamine, triethanolamine, tromethamine, methylglucamine, glucosamine.

17. The composition of claim 1, wherein said formulation has a pH, said biologically active agent has a negative charge at said formulation pH and said non-volatile counterion comprises a strong base.

18. The composition of claim 17, wherein said strong base has at least one pKa higher than about 12.

19. The composition of claim 18, wherein said strong base is selected from the group consisting of sodium hydroxide, potassium hydroxide, calcium hydroxide, and magnesium hydroxide.

20. The composition of claim 1, wherein said formulation has a pH, said biologically active agent has a negative charge at said formulation pH and said non-volatile counterion comprises a basic zwitterion.

21. The composition of claim 20, wherein said basic zwitterion has at least two basic pKas and at least one acidic pKa, so that there is at least one basic pKa more than acidic pKas.

22. The composition of claim 21, wherein said basic zwitterion is selected from the group consisting of histidine, lysine, and arginine.

23. The composition of claim 1, wherein said formulation has a pH, said biologically active agent has a positive charge at said formulation pH and said non-volatile counterion comprises a mixture of counterions comprising at least one non-volatile strong acid and at least one non-volatile weak acid.

24. The composition of claim 1, wherein said formulation has a pH, said biologically active agent has a negative charge at said formulation pH and said non-volatile counterion comprises a mixture of counterions comprising at least one non-volatile strong base and at least one non-volatile weak base.

25. The composition of claim 1, wherein said formulation has a pH, said biologically active agent has a positive charge at said formulation pH and said volatile counterion comprises a volatile weak acid.

26. The composition of claim 25, wherein said volatile weak acid has an acidic pKa higher than approximately 2 and a property selected from the group consisting of a melting point lower than about 50°

C. and a boiling point lower than about 170°

C. at P_atm.

27. The composition of claim 26, wherein said volatile weak acid is selected from the group consisting of acetic acid, propionic acid and pentanoic acid.

28. The composition of claim 1, wherein said formulation has a pH, said biologically active agent has a negative charge at said formulation pH and said volatile counterion comprises a volatile weak base.

29. The composition of claim 28, wherein said volatile weak acid has a basic pKa lower than approximately 12 and a property selected from the group consisting of a melting point lower than about 50°

C. and a boiling point lower than about 170°

C. at P_atm.

30. The composition of claim 29, wherein said volatile weak base is selected from the group consisting of ammonia and morpholine.

31. The composition of claim 1, wherein said biologically active agent is selected from the group consisting of growth hormone release hormone (GHRH), growth hormone release factor (GHRF), insulin, insultropin, calcitonin, octreotide, endorphin, TRN, NT-36 (chemical name:

N-[[(s)-4-oxo-2-azetidinyl]carbonyl]-L-histidyl-L-prolinamide), liprecin, pituitary hormones (e.g., HGH, HMG, desmopressin acetate, etc), follicle luteoids, aANF, growth factors such as growth factor releasing factor (GFRF), bMSH, GH, somatostatin, bradykinin, somatotropin, platelet-derived growth factor releasing factor, asparaginase, bleomycin sulfate, chymopapain, cholecystokinin, chorionic gonadotropin, erythropoietin, epoprostenol (platelet aggregation inhibitor), gluagon, HCG, hirulog, hyaluronidase, interferon alpha, interferon beta, interferon gamma, interleukins, interleukin-10 (IL-10), erythropoietin (EPO), granulocyte macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), glucagon, leutinizing hormone releasing hormone (LHRH), LHRH analogs (such as goserelin, leuprolide, buserelin, triptorelin, gonadorelin, and napfarelin, menotropins (urofollitropin (FSH) and LH)), oxytocin, streptokinase, tissue plasminogen activator, urokinase, vasopressin, deamino [Val4, D-Arg8] arginine vasopressin, desmopressin, corticotropin (ACTH), ACTH analogs such as ACTH (1-24), ANP, ANP clearance inhibitors, angiotensin II antagonists, antidiuretic hormone agonists, bradykinn antagonists, ceredase, CSI'"'"'s, calcitonin gene related peptide (CGRP), enkephalins, FAB fragments, IgE peptide suppressors, IGF-1, neurotrophic factors, colony stimulating factors, parathyroid hormone and agonists, parathyroid hormone antagonists, parathyroid hormone (PTH), PTH analogs such as PTH (1-34), prostaglandin antagonists, pentigetide, protein C, protein S, renin inhibitors, thymosin alpha-1, thrombolytics, TNF, vasopressin antagonists analogs, alpha-1 antitrypsin (recombinant), and TGF-beta.

32. The composition of claim 1, wherein said biologically active agent comprises a fentanyl-based agent selected from the group consisting of fentanyl, fentanyl base, fentanyl salt, alpha-methyl fentanyl, 3-methyl fentanyl, methyl fentanyl, remifentanyl, sufentanyl, alfentanyl, lofentanyl and carfentanyl.

33. The composition of claim 32, wherein said fentanyl salt is formed in conjunction with an ion selected from the group consisting of acetate, propionate, butyrate, pentanoate, hexanoate, heptanoate, levulinate, chloride, bromide, citrate, succinate, maleate, glycolate gluconate, glucuronate, 3-hydroxyisobutrate, 2-hydroxyisobutyrate, lactate, malate, pyruvate, fumarate, tartarate, tartronate, nitrte, phosphate, benzene sulfonate, methane sulfonate, sulfate, sulfonate, tricarballylicate, malonate, adipate, citraconate, glutarate, itaconate, mesaconate, citramalate, dimethylolpropionate, tiglicate, glycerate, methacrylate, isocrotonate, b-hydroxybutyrate, crotonate, angelate, hydracrylate, ascorbate, aspartate and glutamate.

34. The composition of claim 31, wherein said formulation includes said fentanyl-based agent in the range of approximately 1-60 wt. % of said formulation.

35. The composition of claim 34, wherein said formulation includes said fentanyl-based agent in the range of approximately 5-30 wt. % of said formulation.

36. The composition of claim 31, wherein said formulation has a pH in the range of approximately 1-6.

37. The composition of claim 36, wherein said formulation has a pH in the range of approximately 2-5.5.

38. The composition of claim 1, wherein said formulation further comprises a formulation adjuvant.

39. The composition of claim 38, wherein said formulation adjuvant comprises a buffer.

40. The composition of claim 38, wherein said formulation adjuvant comprises an antioxidant.

41. The composition of claim 38, wherein said formulation adjuvant comprises a surfactant.

42. The composition of claim 38, wherein said formulation adjuvant comprises an amphiphilic polymer.

43. The composition of claim 38, wherein said formulation adjuvant comprises a hydrophilic polymer.

44. The composition of claim 38, wherein said formulation adjuvant comprises a biocompatible carrier.

45. The composition of claim 38, wherein said formulation adjuvant comprises a stabilizing agent.

46. The composition of claim 38, wherein said formulation adjuvant comprises a vasoconstrictor.

47. The composition of claim 38, wherein said formulation adjuvant comprises a pathway patency modulator.

48. The composition of claim 38, wherein said formulation adjuvant comprises a solubilising/complexing agent.

49. The composition of claim 38, wherein said formulation adjuvant comprises a non-aqueous solvent.

50. The composition of claim 1, wherein said formulation has a viscosity less than about 500 centipoise and greater than about 3 centipoise.

51. The composition of claim 1, further comprising a transdermal delivery device having at least one microprojection configured to pierce the stratum corneum, wherein said formulation is coated on said microprojection and dried.

52. The device of claim 51, wherein said formulation coated on said microprojection has a thickness less than approximately 25 microns.

53. The device of claim 52, wherein said formulation coated on said microprojection has a thickness less than approximately 10 microns.

6. The composition of claim 6, wherein said non-volatile weak acid has an acidic pKa and a property selected from the group consisting of a melting point higher than about 50°

C. and a boiling point higher than about 170°

C. at atmospheric pressure.

7. The composition of claim 6, wherein said non-volatile weak acid is selected from the group consisting of citric acid, succinic acid, glycolic acid, gluconic acid, glucuronic acid, lactic acid, malic acid, pyruvic acid, tartaric acid, tartronic acid, and fumaric acid.

54. A method for transdermally delivering a biologically active agent comprising the steps of:

providing a transdermal delivery device having at least one stratum corneum-piercing microprojection, the microprojection including a biocompatible coating comprising a dried formulation of said biologically active agent, a non-volatile counterion and a volatile counterion, wherein said non-volatile counterion causes the formation of a first species of the biologically active agent that has improved solubility when said formulation is dried and said volatile counterion causes the formation of a second species of said biologically active agent that has reduced solubility when said formulation is dried; and

applying said delivery device to a patient to deliver said biologically active agent.

55. The method of claim 54, further comprising the step of rapidly establishing a therapeutically relevant blood level of said agent in said patient by dissolving said first species.

56. The method of claim 55, wherein the step of rapidly establishing a therapeutically relevant blood level of said agent comprises establishing said blood level in less than 30 min after applying said device.

57. The method of claim 56, wherein the step of rapidly establishing a therapeutically relevant blood level of said agent comprises establishing said blood level in less than 15 min after applying said device.

58. The method of claim 55, further comprising the step of maintaining a therapeutically relevant blood level of said agent in said patient by dissolving said second species.

59. The method of claim 58, wherein the step of maintaining a therapeutically relevant blood level of said agent comprises maintaining said blood level in the range of approximately 1 to 6 hours.

60. The method of claim 59, wherein the step of maintaining a therapeutically relevant blood level of said agent comprises maintaining said blood level in the range of approximately 2 to 4 hours.

61. The method of claim 54, wherein said agent comprises a fentanyl-based agent.

62. The method of claim 58, wherein said agent comprises fentanyl and wherein said therapeutically relevant blood level is at least approximately 0.3 ng/mL.

63. The method of claim 62, further comprising the step of delivering said agent in the range of approximately 10 to 1000 mg per day.

64. A method for applying a biocompatible coating to a transdermal delivery device that has a least one stratum corneum-piercing microprojection comprising the steps of:

providing a formulation of a biologically active agent, a non-volatile counterion, and a volatile counterion, wherein said non-volatile counterion causes the formation of a first species of said biologically active agent that has improved solubility when the formulation is dried and wherein said volatile counterion causes the formation of a second species of said biologically active agent that has reduced solubility when said formulation is dried;

applying said formulation to said microprojection; and

drying said formulation.